[go: up one dir, main page]

WO2002008178A1 - New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation - Google Patents

New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation Download PDF

Info

Publication number
WO2002008178A1
WO2002008178A1 PCT/SE2001/001651 SE0101651W WO0208178A1 WO 2002008178 A1 WO2002008178 A1 WO 2002008178A1 SE 0101651 W SE0101651 W SE 0101651W WO 0208178 A1 WO0208178 A1 WO 0208178A1
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
antagonist
htg
agonist
disease
Prior art date
Application number
PCT/SE2001/001651
Other languages
English (en)
French (fr)
Inventor
Sukhwinder Jossan
Björn M. NILSSON
Kjell S. Sakariassen
Jan Svartengren
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL15405701A priority Critical patent/IL154057A0/xx
Priority to KR1020037000321A priority patent/KR100845450B1/ko
Priority to HU0301346A priority patent/HUP0301346A3/hu
Priority to AU2001282734A priority patent/AU2001282734B2/en
Priority to NZ523216A priority patent/NZ523216A/en
Priority to BR0112661-0A priority patent/BR0112661A/pt
Priority to EP01961472A priority patent/EP1301476A1/en
Priority to HK04100306.5A priority patent/HK1057536B/xx
Priority to CA002411192A priority patent/CA2411192A1/en
Priority to MXPA03000548A priority patent/MXPA03000548A/es
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Priority to AU8273401A priority patent/AU8273401A/xx
Priority to JP2002514087A priority patent/JP2004504376A/ja
Priority to EA200300183A priority patent/EA006604B1/ru
Priority to PL36030901A priority patent/PL360309A1/xx
Publication of WO2002008178A1 publication Critical patent/WO2002008178A1/en
Priority to NO20030304A priority patent/NO20030304L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to the prophylaxis or treatment of a 5-HT 2 c and a 5-HT 6 receptor-related disease.
  • the invention provides a pharmaceutical composition containing a 5-HT 2 c receptor agonist and a 5-HT 6 receptor antagonist for therapeutic use.
  • Serotonin (5-hydroxytryptamine or 5-HT) is a key neurotransmitter of the peripheral and central nervous system (PNS and CNS) and has been implicated in a variety of sensory, motor and behavioral functions such as regulation of eating, sleeping, body temperature, blood pressure, emotions and cognition. At least 14 distinct serotonin receptor subtypes are expressed in the mammalian PNS and CNS and have been formally classified; see Glennon, et al., Neiirosci Biobehav. Rev. 1990, 14, 35-37; and D. Hoyer, et al., Pharmacol. Rev. 1994, 46, 157-203.
  • Serotoninergic agonists and antagonists have been suggested for the treatment of a wide range of disorders, including anxiety, depression, hypertension, migraine, obesity, drug abuse and addiction, compulsive disorders, schizophrenia, autism, neurodegenerative disorders (e.g. Alzheimer's disease, Parkinsonism, and Huntington's chorea), and chemotherapy- induced vomiting.
  • the 5-HT 2 subfamily of receptors is composed of three subtypes, the 5-HT2A > 5- HT2B and 5-HT 2 c receptors. Serotonin 5-HT2C receptors are expressed in many brain regions and have been implicated in the regulation of food intake (Dourish, C.T. Obes. Res. 1995, 3, Suppl 4, 449S-462S; Bickerdike, M.J., et al. Diabetes, Obes. Metab. 1999, 1, 207-214).
  • the 5-HT2C receptor subtype has also been suggested to be involved in CNS disorders, such as depression and anxiety (Jenck, F., et al. Expert Opin. Invest. Drugs 1998, 7, 1587-1599; Leysen, D.C.M. IDrugs 1999, 2, 109-120).
  • the 5-HT 2 c receptor subtype has further been suggested to be involved in urinary disorders such as urinary incontinence (Leysen, D.C.M. IDrugs 1999, 2, 109-120).
  • 5-HTg receptor (identified in 1993 - Monsma et al., Mol. Pharmacol. 1993, 43, 320-327 and Ruat, M. et al. Biochem. Biophys. Res. Commun. 1993, 193, 269- 276) has been implicated in the regulation of food intake and CNS disorders.
  • 5-HTg receptor has been linked to generalized stress and anxiety states (Yoshioka et al. Life Sci. 1998, 17/18, 1473-1477).
  • a 5-HT 2 c receptor agonist and a 5-HTg receptor antagonist reduces food intake by more than the administration of either agonist or antagonist alone.
  • Such combined administration of a 5-HT 2 c receptor agonist and a 5-HTg receptor antagonist may offer therapeutic advantages as compared to treatment with either agonist or antagonist alone.
  • One aspect of the present invention therefore provides a pharmaceutical composition comprising an effective amount of a combination of a 5-HT 2 c receptor agonist and a 5-HT6 receptor antagonist, and optionally a pharmaceutically acceptable carrier.
  • Another aspect of the invention provides a method of preventing or treating a disease, in particular obesity, related to the 5-HT2C receptor and the 5-HTg receptor, comprising administering to a human or animal subject in need thereof a 5-HT 2 c receptor agonist and a 5-HT receptor antagonist (simultaneously or sequentially) in sufficient amounts to provide a therapeutic effect.
  • Still another aspect of the invention provides the use of a 5-HT 2 c receptor agonist and a 5-HTg receptor antagonist for the manufacture of a medicament for the treatment of a disease related to the 5-HT 2 c receptor and the 5-HT6 receptor.
  • Another aspect of the invention provides a process for preparing a pharmaceutical composition, wherein a 5-HT ; receptor agonist and a 5-HTg receptor antagonist in a combined therapeutic amount are intimately mixed with a pharmaceutically acceptable carrier.
  • Yet another aspect of the invention provides a product containing a 5 ⁇ HT 2 c receptor agonist and a 5-HTg receptor antagonist as a combined preparation for simultaneous, separate or sequential use in therapy of a disease, in particular obesity, related to the 5-HT 2 c receptor and the 5-HTg receptor.
  • Figure 1 shows the effect on food intake in ob/ob mice following combined administration with a 5-HT 2 c receptor agonist (PNU- 183933F; 50 mg kg po) and a 5- HTg receptor antagonist (PNU- 186053 A; 50 mg/kg sc), as well as the effect of each agonist and antagonist alone.
  • Figure 2 shows the effect on food intake in ob/ob mice following combined administration of a 5-HT 2C receptor agonist (BVT.2938F; 5 mg/kg sc) and a 5-HT 6 receptor antagonist (BVT.5182C; 3 mg/kg sc), as well as the effect of each agonist and antagonist alone.
  • BVT.2938F 5-HT 2C receptor agonist
  • BVT.5182C 5-HT 6 receptor antagonist
  • the present invention is based on the unexpected finding that combined administration of a 5-HT 2 c receptor agonist and a 5-HTg receptor antagonist reduces food intake more than either agonist or antagonist alone.
  • Such combined administration of a 5-HT 2 c receptor agonist and a 5-HTg receptor antagonist may also offer several benefits, for instance in the treatment of obesity, as compared to treatment with either agonist or antagonist alone. Firstly, the combined administration requires lower doses of each compound to yield similar or improved reduction of food intake than mono-therapy.
  • the lower doses required by the combined administration may reduce the risk of adverse events.
  • the lower doses required by the combined administration may reduce the risk of tolerance development and abuse liability.
  • therapy based on two targets may increase the individual therapeutic efficacy relative to therapy based on one target.
  • the risk of non-responsive efficacy may be reduced as well.
  • the beneficial effects of the combined administration of this invention is useful not only for the modulation of eating behavior, and for treating over- weight and obesity, but may also be useful for the treatment of CNS disorders such as, depression, mania, schizophreniform disorders, anxiety, memory disorders (such as Alzheimer's disease) migraine headache, drug addiction, convulsive disorders, personality disorders, post- traumatic stress syndrome, and sleep disorders as well as for treatment of urinary incontinence (or more generally overactive bladder), sexual dysfunctions, gastrointestinal disorders and glaucoma.
  • CNS disorders such as, depression, mania, schizophreniform disorders, anxiety, memory disorders (such as Alzheimer's disease) migraine headache, drug addiction, convulsive disorders, personality disorders, post- traumatic stress syndrome, and sleep disorders as well as for treatment of urinary incontinence (or more generally overactive bladder), sexual dysfunctions, gastrointestinal disorders and glaucoma.
  • 5-HT 2C receptor agonist refers to a compound that causes activation of the serotonin 5-HT 2 c receptor.
  • the 5-HT 2 c receptor agonist preferably has an affinity constant, Kj, of less than 50 nM, preferably less than 20 nM, and an in vitro intrinsic activity, measured as intracellular Ca 2+ levels, greater than 20%, preferably greater than 50%, relative to 5-HT (1 ⁇ M).
  • the term "5-HT ⁇ receptor antagonist” as used herein refers to a compound that causes blockade of the serotonin 5-HT6 receptor mediated responses.
  • the 5-HTg receptor antagonist preferably has an affinity constant, Kj, of less than 50 nM, preferably less than 20 nM, and an in vitro intrinsic activity, measured as intracellular cAMP levels, less than 50%, preferably less than 20%, relative to 5-HT (1 ⁇ M).
  • the 5-HT2C receptor agonists and 5-HT6 receptor antagonists should be sufficiently selective not to cause any substantial adverse side effects.
  • selective and substantially in this context are, however, to be interpreted broadly, the meanings thereof being readily apparent to the skilled person.
  • the 5-HT 2 c receptor agonist preferably has a selectivity for the 5-HT 2 c receptor of at least 5, preferably at least 10 and more preferably at least 20, relative to the 5- HT 2A , 5-HT 2 B and 5-HTg receptors, respectively (measured as the affinity ratios 5- HT 2A /5-HT 2C , 5-HT 2B /5-HT 2C and 5-HT 6 /5-HT 2C ).
  • the 5-HTg receptor antagonist preferably has a selectivity for the 5-HTg receptor of at least 5, preferably at least 10 and more preferably at least 20, relative to the 5-HT 2j > 5-HT 2J3 and 5-HT 2 c receptors, respectively (measured as the affinity ratios 5-HT 2A /5-HT 6 , 5-HT 2B /5-HT 6 and 5-HT 2c /5-HT 6 ).
  • Relevant tests to determine whether a compound is a selective 5-HT 2 c receptor agonist or a selective 5-HTg receptor antagonist are known in the art, and are, as mentioned above, also outlined in the Experimental Part below.
  • Compounds known to be 5-HT 2C receptor agonists are, for example, azetidine and pyrrolidine derivatives of the type described in EP-A-0863136; tricyclic pyrrole derivatives of the type described in EP-A-0657426; 1-aminoethylindoles of the type described in EP-A-0655440; pyrazinoindoles of the type described in EP-A-0572863; piperazinylpyrazines of the type described in US 4,081,542; indoline derivatives of the type described in WO 00/12475; pyrroloindoles, pyridoindoles and azepinoindoles of the type described in WO 00/12510; indazole derivatives of the type described in WO 00/12482; pyrroloquinolines of the type described in WO 00/12502; 2,3,4,4a- tetrahydro-lH-pyrazino[l,2-a]
  • 5- ⁇ T 2 c receptor agonists are of the arylpiperazine and piperazinylpyrazine compound classes, in particular compounds disclosed in WO 00/76984 and in Swedish patent applications Nos. 0004244-0 and 0004245-7, filed on 20 November 2000.
  • Compounds known to be 5-HTg receptor antagonists are, for example, piperazinylbenzenesulfonamides of the type described in WO 99/37623; sulfonylbenzene derivatives of the type described in EP-A-0930302; sulfonamide derivatives of the type described in WO 99/02502; sulfonamide derivatives of the type described in WO 99/42465; sulfonamide derivatives of the type described in WO 98/27081 ; carboxamide derivatives of the type described in WO 98/27058; sulfonamide derivatives of the type described in EP-A-0815861; pyrrolidonomethylindole derivatives of the type described in WO 99/47516; bicyclic piperidine and piperazine derivatives of the type described in WO 99/65906; pyrazolopyrimidine and pyrazolotriazine derivatives of the type described in EP-A-0941994; ary
  • preferable 5-HTg receptor antagonists include the azepinoindole compound class, such as the class of arylsulfone-substituted hexahydroazepinoindoles compounds disclosed in WO 01/05793.
  • Other preferred 5-HTg receptor antagonists include the arylsulfonylindole compound class, such as the compound class described in the Swedish patent application No. 0003810-9.
  • the 5-HT 2C receptor agonists and the 5-HTg receptor antagonists may be the compounds as such or where appropriate the pharmaceutically acceptable salts (acid or base addition salts) thereof or stereochemically isomeric forms thereof (including optical isomers, such as enantiomers and racemates).
  • the pharmaceutically acceptable addition salts as mentioned above are meant to comprise the therapeutically active non-toxic acid and base addition salt forms which the compounds are able to form.
  • Compounds which have basic properties can be converted to their pharmaceutically acceptable acid addition salts by treating the base form with an appropriate acid.
  • Exemplary acids include inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulphuric acid, phosphoric acid; and organic acids such as acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, benzenesulfonic acid, toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, malic acid, tartaric acid, citric acid, salicylic acid, p-aminosalicylic acid, pamoic acid, benzoic acid, ascorbic acid and the like.
  • organic acids such as acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, benzenesulfonic acid, toluenesulf
  • Exemplary base addition salt forms are the sodium, potassium, calcium salts, and salts with pharmaceutically acceptable amines such as, for example, ammonia, alkylamines, benzathine, and amino acids, such as, e.g. arginine and lysine.
  • the term addition salt as used herein also comprises solvates which the compounds and salts thereof are able to form, such as, for example, hydrates, alcoholates and the like.
  • the 5-HT 2 c receptor agonists and the 5-HTg receptor antagonists may also be prodrugs or forms that may release the active ingredient in question after metabolic tranformation in vivo. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs" ed. H.
  • the 5-HT2C receptor agonists and the 5-HTg receptor antagonists may be formulated into various pharmaceutical forms for administrative purposes, either in the same pharmaceutical dosage form, such as in the same tablet, or in separate pharmaceutical dosage forms. In the latter case, however, it may be advantageous to put the 5-HT2C receptor agonist unit dosage form and the 5-HTg receptor antagonist unit dosage form in the same package, for example in the same blister.
  • the 5-HT 2 c receptor agonists and the 5-HTg receptor antagonists in the form of free bases or salt, can be brought into suitable galenic forms, such as compositions for oral use, for injection, for nasal spray administration or the like, in accordance with accepted pharmaceutical procedures.
  • suitable galenic forms such as compositions for oral use, for injection, for nasal spray administration or the like, in accordance with accepted pharmaceutical procedures.
  • Such pharmaceutical compositions according to the invention comprise an effective amount of a 5-HT 2 c receptor agonist and a 5-HTg receptor antagonist in association with compatible pharmaceutically acceptable carrier materials, or diluents, as are well known in the art.
  • the carriers may be any inert material, organic or inorganic, suitable for oral, enteral, rectal, percutaneous, subcutaneous or parenteral administration, such as: water, gelatin, gum arabicum, lactose, macrocrystalline cellulose, starch, sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talcum, colloidal silicon dioxide, and the like.
  • Such compositions may also contain other pharmacologically active agents, and conventional additives, such as stabilizers, wetting agents, emulsifiers, flavoring agents, buffers, and the like.
  • compositions according to the invention can e.g. be made up in solid or liquid form for oral administration, such as tablets, pills, capsules, powders, syrups, elixirs, dispersable granules, cachets, suppositories and the like, in the form of sterile solutions, suspensions or emulsions for parenteral administration, sprays, e.g. a nasal spray, transdermal preparations, e.g. patches, and the like.
  • each of the specific 5-HT 2 c receptor agonist and 5-HTg receptor antagonist, and the frequency of dosage of the specific combination will vary depending on a variety of factors including the potency of each specific compound employed, the metabolic stability and length of action of that compound, the patient's age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the condition to be treated).
  • the daily dosage may, for example, range from about 0.001 mg to about 150 mg per kilo of body weight, preferably from about 0.01 mg to about 100 mg per kilo of body weight, especially from about 0.1 to about 50 mg per kilo of body weight of each of the 5-HT 2 c receptor agonist and of the 5-HTg receptor antagonist, administered singly or multiply in doses, e.g. dosages of from about 0.01 mg to about 1 g each.
  • a combined dosage is given orally but e.g. parenteral or rectal administration may also be chosen.
  • An exemplary tablet combination formulation may be in the form of either (A) two separate tablets, i.e.
  • the 5-HT 6 receptor antagonist 6-methyl-9-(phenylsulfonyl)-l, 2,3, 4,5,6- hexahydroazepino[4,5-b]indole, hydrochloride (“PNU- 186053 A”) was prepared as described in WO 01/05793.
  • the 5-HT 2C receptor agonist (2R)-l-(3- ⁇ 2-[(2-ethoxy-3-pyridinyl)oxy]ethoxy ⁇ -2- pyrazinyl)-2-methylpiperazine, fumarate (“B VT.2938F”) was prepared as described in WO 00/76984.
  • BVT.5182C The 5-HT 6 receptor antagonist l-(phenylsulfonyl)-4-(l-piperazinyl)-lH-indole, hydrochloride
  • BVT.5182C was prepared as described in Swedish patent application No. 0003810-9, filed on October 20, 2000. Briefly, BVT.5182C was prepared according the general procedure depicted in Scheme 1, below, starting from commercially available 4-piperazinoindole (compound 1) that undergoes steps (a) to (c) to afford 1- (phenylsulfonyl)-4-(l-piperazinyl)-lH-indole, hydrochloride (yield 80%).
  • the intermediate 2 (1.0 eq) was dissolved in DMF and Na ⁇ (1.3 eq) was added and the suspension was stirred for 0.5 h under nitrogen atmosphere. Benzenesulfonyl chloride (1.2 eq) was added and the reaction was stirred overnight at room temperature. The volatiles were evaporated.
  • the BOC group on intermediate 3 was removed by dissolving the compound in methanol followed by addition of ether saturated with HC1 gas.
  • the HC1 salt (4) was filtered and dried.
  • the active ingredients 1 and 2 are mixed with ingredients 3, 4, 5 and 6 for about 10 minutes.
  • the magnesium stearate (7) is then added, and the resultant mixture is mixed for about 5 minutes and compressed into tablet form with or without film-coating.
  • 5-HT 2 c receptor affinity is determined in competition experiments, where the ability of a compound in serial dilution to displace 3 H-labeled 5-HT, bound to membranes prepared from a transfected HEK293 cell line stably expressing the human 5-HT 2 c receptor protein, is monitored by Scintillation Proximity Assay (SPA) technology. Non-specific binding is defined using 5 ⁇ M mianserin.
  • 5-HT 2A receptor affinity is determined in competition experiments, where the ability of a compound in serial dilution to displace 3 H-labeled ketanserin or lysergic acid diethylamide (LSD), bound to membranes prepared from a transfected CHO cell line stably expressing the human 5-HT 2 A receptor protein, is monitored by measuring the radioactivity of filtered membrane homogenates on glass fiber filters in a scintillation counter. Non-specific binding is defined using 5 ⁇ M mianserin.
  • 5-HT2B receptor affinity assay 5-HT2B receptor affinity is determined in competition experiments, where the ability of a compound in serial dilution to displace ⁇ H-labeled 5-HT, bound to membranes prepared from a transfected CHO cell line stably expressing the human 5- HT2B receptor protein, is monitored by Scintillation Proximity Assay (SPA) technology. Non-specific binding is defined using 5 ⁇ M mianserin.
  • SPA Scintillation Proximity Assay
  • the agonist efficacy at the 5-HT 2 c receptor is determined by the ability of a compound to mobilise intracellular calcium in transfected HEK293 cells, stably expressing the human 5-HT 2 c receptor protein, using the calcium-chelating fluorescent dye FLUO-3 (Sigma, St. Louis, MO, U.S.A.). Relative efficacy (%) is measured relative to that of serotonin at 1 ⁇ M.
  • the radioligand binding assay uses [ 3 H]-lysergic acid diethylamide (LSD).
  • LSD [ 3 H]-lysergic acid diethylamide
  • the assay is carried out in 96-well sample plates by the addition of 11 ⁇ l of the test compound at the appropriate dilution (the assay employs 11 serial concentrations of samples run in duplicate), 11 ⁇ l of radioligand, and 178 ⁇ l of a washed mixture of WGA-coated SPA beads and membranes in binding buffer prepared from HEK293- cells containing cloned human 5-HT5 receptor.
  • the plates are shaken for about 5 minutes and then incubated at room temperature for 1 hour.
  • the plates are then loaded into counting cassettes and counted in a scintillation counter.
  • the specifically bound cpm obtained are fit to a one-site binding model using GraphPad Prism ver. 2.0.
  • Estimated IC 50 values are converted to Kj (affinity constant) values using the Cheng- Prusoff equation (Cheng, Y. C. et al., Biochem. Pharmacol. 1973, 22, 3099-3108).
  • the antagonist potency at the 5-HTg receptor is determined by the ability of a compound to antagonize the increase in cAMP induced by 5-HT in HEK293 cells, stably expressing the human 5-HTg receptor protein, using a cAMP SPA direct screening assay system (RPA559, Amersham Pharmacia Biotech, Uppsala, Sweden).
  • 5-HT2C receptor agonists (2i?)-methyl-l- ⁇ 3-[2-(3-pyridinyloxy)ethoxy]-2- pyrazinyl ⁇ piperazine, fumarate (“PNU-183933F”) and (2 ⁇ )-l-(3- ⁇ 2-[(2-ethoxy-3- pyridinyl)oxy]ethoxy ⁇ -2-pyrazinyl)-2-methylpiperazine, fumarate (“BVT.2938F”) were dissolved in saline (0.9% NaCl) and diluted in the same vehicle to the appropriate concentration.
  • mice Male mice 8-9 weeks old (C57BL/6JBom-Lep ob (ob/ob), Bomholtsgaard,
  • mice were housed singly in cages at 23+l°C, 40-60% humidity and had free access to water and standard laboratory chow.
  • the 12/12 h light/dark cycle was set to lights off at 5 p.m.
  • the animals were conditioned for at least one week before start of study. During experimental sessions, the animals obtained special chow (BioServ, Frenchtown, NJ, USA dust-free precision pellets weighing 20 mg each).
  • the compounds were administered between 4.20 and 5.00 p.m. before dark onset.
  • Three groups of animals received (i) 5-HTg antagonist in 25% cyclodextrin; (ii) 5-HT 2 c agonist in saline; and (iii) the combination 5-HT 2 c agonist/5-HT6 antagonist, respectively.
  • 5-HT6 antagonist or saline was administered 30 min before administration of the 5-HT 2 c agonist or 25% cyclodextrin.
  • a fourth group received respectively vehicle administered in the same way. The study ended on the fifth day. Weighing was performed with a computer- assisted Mettler-Toledo PR5002/PR802 balance.
  • Each dose group consisted of 12-16 animals. Data were corrected for food spillage based on the weighed spillage during 22 hours and assumed to be proportional over time. Calculations were performed for the data before and after treatment. The values were expressed as % of basal food intake (mean ⁇ SEM) for the difference between food intake before treatment and 3 h (5 pm - 8 pm), 6 h (5 pm - 11 pm), 12 h (5 pm - 5 am), 21 h (5 pm - 2 pm).
  • Fig. 1 The results shown in Fig. 1 indicate that combined treatment with the 5-HTg receptor antagonist "PNU- 186053 A" (50 mg/kg subcutaneously) and the 5-HT2C receptor agonist "PNU-183933F” (50 mg/kg per orally) decreased food consumption significantly more than the compounds given alone.
  • the results shown in Fig. 2 indicate that combined treatment with the 5-HT2 receptor agonist "BVT.2938F” (5 mg/kg subcutaneously) and the 5-HTg receptor antagonist "BVT.5182C” (3 mg/kg subcutaneously) decreased food consumption, at 12 and 21 hours following administration, significantly more than the compounds given alone.
  • a 5-HT2C receptor agonist and a 5-HTg receptor antagonist reduces food intake more efficiently as compared to treatment with either agonist or antagonist alone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
PCT/SE2001/001651 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation WO2002008178A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CA002411192A CA2411192A1 (en) 2000-07-21 2001-07-19 Combination of serotonin agonist (5ht2) and antagonist (5ht6)as a pharmaceutical formulation
HU0301346A HUP0301346A3 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical composition and process for its preparation
AU2001282734A AU2001282734B2 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
NZ523216A NZ523216A (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5HT2) and antagonist (5HT6) as pharmaceutical formulation
BR0112661-0A BR0112661A (pt) 2000-07-21 2001-07-19 Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica
EP01961472A EP1301476A1 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
HK04100306.5A HK1057536B (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation
IL15405701A IL154057A0 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation
KR1020037000321A KR100845450B1 (ko) 2000-07-21 2001-07-19 약학적 제형물로서의 세로토닌 아고니스트 (5에이치티2)및 안타고니스트 (5에이치티6) 의 새로운 조합
MXPA03000548A MXPA03000548A (es) 2000-07-21 2001-07-19 Combinacion novedosa de agonista (5-ht2) y antagonistas (5-ht6) de serotonina como formulacion farmaceutica.
AU8273401A AU8273401A (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
JP2002514087A JP2004504376A (ja) 2000-07-21 2001-07-19 医薬製剤としてのセロトニンアゴニスト（５ｈｔ２）とアンタゴニスト（５ｈｔ６）の新規組み合わせ
EA200300183A EA006604B1 (ru) 2000-07-21 2001-07-19 Сочетание агониста (5-ht2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции
PL36030901A PL360309A1 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
NO20030304A NO20030304L (no) 2000-07-21 2003-01-20 Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasoytisk formulering

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002754-0 2000-07-21
SE0002754A SE0002754D0 (sv) 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination

Publications (1)

Publication Number Publication Date
WO2002008178A1 true WO2002008178A1 (en) 2002-01-31

Family

ID=20280577

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2001/001651 WO2002008178A1 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation

Country Status (18)

Country Link
EP (1) EP1301476A1 (hu)
JP (1) JP2004504376A (hu)
KR (1) KR100845450B1 (hu)
CN (1) CN1221254C (hu)
AU (2) AU8273401A (hu)
BR (1) BR0112661A (hu)
CA (1) CA2411192A1 (hu)
EA (1) EA006604B1 (hu)
HU (1) HUP0301346A3 (hu)
IL (1) IL154057A0 (hu)
MX (1) MXPA03000548A (hu)
NO (1) NO20030304L (hu)
NZ (1) NZ523216A (hu)
PL (1) PL360309A1 (hu)
SE (1) SE0002754D0 (hu)
WO (1) WO2002008178A1 (hu)
YU (1) YU2603A (hu)
ZA (1) ZA200210234B (hu)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102774A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
WO2002036562A3 (en) * 2000-11-02 2003-01-23 Wyeth Corp 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
WO2003066632A1 (en) * 2002-02-05 2003-08-14 Glaxo Group Limited Sulphonyl compounds with 5 -ht6 receptor affinity
US6894050B2 (en) 2001-06-21 2005-05-17 Pfizer Inc. 5-HT receptor ligands and uses thereof
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
JP2006524679A (ja) * 2003-04-25 2006-11-02 ファイザー・インク 失禁の治療
WO2007076875A3 (en) * 2006-01-06 2007-11-15 Univ Aarhus Compounds acting on the serotonin transporter
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
WO2007149728A3 (en) * 2006-06-20 2008-07-03 Alcon Res Ltd Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
US7452888B2 (en) 2002-03-27 2008-11-18 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
EP2020230A1 (en) * 2007-08-01 2009-02-04 Laboratorios del Dr. Esteve S.A. Combination of at least two 5-HT6-Ligands
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
EP2248524A2 (en) 2004-08-25 2010-11-10 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
WO2010147226A1 (en) 2009-06-15 2010-12-23 Takeda Pharmaceutical Company Limited Pyrazinooxazepine derivatives
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
US8063053B2 (en) 2008-11-11 2011-11-22 Wyeth Llc 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as 5-hydroxytryptamine-6 ligands
US9745270B2 (en) 2008-10-28 2017-08-29 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
US9775829B2 (en) 2003-07-22 2017-10-03 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US9808455B2 (en) 2007-12-12 2017-11-07 Axovant Sciences Gmbh Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
US10034859B2 (en) 2015-07-15 2018-07-31 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
US10059691B2 (en) 2008-04-02 2018-08-28 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用
CN111269165A (zh) * 2018-12-05 2020-06-12 中国科学院大连化学物理研究所 一种3-芳基磺酰基吲哚衍生物的合成方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments
WO1999042465A2 (en) * 1998-02-18 1999-08-26 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
WO1999047516A1 (en) * 1998-03-16 1999-09-23 Abdelmalik Slassi 3-(2-pyrrolidinylmethyl)-indole compounds having 5-ht6 affinity
WO1999065906A1 (en) * 1998-06-15 1999-12-23 Allelix Biopharmaceuticals Inc. Bicyclic piperidine and piperazine compounds having 5-ht6 receptor affinity
WO2000012510A1 (en) * 1998-09-01 2000-03-09 Vernalis Research Limited Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027081A1 (en) * 1996-12-19 1998-06-25 Smithkline Beecham Plc Sulphonamide derivatives, process for their preparation, and their use as medicaments
WO1999042465A2 (en) * 1998-02-18 1999-08-26 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
WO1999047516A1 (en) * 1998-03-16 1999-09-23 Abdelmalik Slassi 3-(2-pyrrolidinylmethyl)-indole compounds having 5-ht6 affinity
WO1999065906A1 (en) * 1998-06-15 1999-12-23 Allelix Biopharmaceuticals Inc. Bicyclic piperidine and piperazine compounds having 5-ht6 receptor affinity
WO2000012510A1 (en) * 1998-09-01 2000-03-09 Vernalis Research Limited Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BRYAN L. ROTH ET AL.: "The multiplicity of serotonin receptors: Uselessly diverse molecules or an embarrassment of riches?", THE NEUROSCIENTIST, vol. 6, no. 4, 2000, pages 252 - 262, XP002948187 *
CHERYL P. KORDIK ET AL.: "Pharmacological treatment of obesity: Therapeutic stategies", JOURNAL OF MEDICAL CHEMISTRY, vol. 42, no. 2, 1999, pages 181 - 201, XP002948185 *
COLLIN T. DOURISH: "Multiple serotonin receptors: opportunities for new treatments for obesity?", OBESITY RESEARCH, vol. 3, 1995, pages 449S - 462S, XP002948186 *

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7557098B2 (en) 2000-11-02 2009-07-07 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
WO2002036562A3 (en) * 2000-11-02 2003-01-23 Wyeth Corp 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US7282495B2 (en) 2000-11-02 2007-10-16 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US7541370B2 (en) 2000-11-02 2009-06-02 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
US6790848B2 (en) 2001-06-15 2004-09-14 Syntex (U.S.A.) Llc 4-piperazinylindole derivatives with 5-HT6 receptor affinity
WO2002102774A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
US6894050B2 (en) 2001-06-21 2005-05-17 Pfizer Inc. 5-HT receptor ligands and uses thereof
WO2003066632A1 (en) * 2002-02-05 2003-08-14 Glaxo Group Limited Sulphonyl compounds with 5 -ht6 receptor affinity
US7601837B2 (en) 2002-03-27 2009-10-13 Glaxo Group Limited Quinoline derivatives and their use as 5-HT6 ligands
US7452888B2 (en) 2002-03-27 2008-11-18 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
US8236947B2 (en) 2002-03-27 2012-08-07 Glaxo Group Limited Quinoline derivatives and their use as 5-HT6 ligands
US7977337B2 (en) 2002-03-27 2011-07-12 Glaxo Group Limited Quinoline derivatives and their use as 5-HT6 ligands
JP2009235080A (ja) * 2002-03-27 2009-10-15 Glaxo Group Ltd キノリン誘導体および５−ｈｔ６リガンドとしてのその使用
US7799774B2 (en) 2002-03-27 2010-09-21 Glaxo Group Limited Quinoline derivatives and their use as 5-HT6 ligands
JP2006524679A (ja) * 2003-04-25 2006-11-02 ファイザー・インク 失禁の治療
US9775829B2 (en) 2003-07-22 2017-10-03 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US8685924B2 (en) 2004-08-25 2014-04-01 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
EP2248524A2 (en) 2004-08-25 2010-11-10 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
WO2007076875A3 (en) * 2006-01-06 2007-11-15 Univ Aarhus Compounds acting on the serotonin transporter
EP2742936A1 (en) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
WO2007149728A3 (en) * 2006-06-20 2008-07-03 Alcon Res Ltd Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
EP2020230A1 (en) * 2007-08-01 2009-02-04 Laboratorios del Dr. Esteve S.A. Combination of at least two 5-HT6-Ligands
ES2355024A1 (es) * 2007-08-01 2011-03-22 Laboratorios Del Dr. Esteve, S.A. Combinacion de al menos dos ligandos de 5ht6.
EP2789338A2 (en) 2007-11-15 2014-10-15 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
WO2009063992A1 (ja) 2007-11-15 2009-05-22 Takeda Pharmaceutical Company Limited 縮合ピリジン誘導体およびその用途
US9808455B2 (en) 2007-12-12 2017-11-07 Axovant Sciences Gmbh Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US10787437B2 (en) 2008-04-02 2020-09-29 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor
US10059691B2 (en) 2008-04-02 2018-08-28 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor
US9745270B2 (en) 2008-10-28 2017-08-29 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
US8063053B2 (en) 2008-11-11 2011-11-22 Wyeth Llc 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as 5-hydroxytryptamine-6 ligands
WO2010147226A1 (en) 2009-06-15 2010-12-23 Takeda Pharmaceutical Company Limited Pyrazinooxazepine derivatives
US9115139B2 (en) 2009-06-15 2015-08-25 Takeda Pharmaceutical Company Limited Pyrazinooxazepine derivatives
US8324201B2 (en) 2009-06-15 2012-12-04 Takeda Pharmaceutical Company Limited Pyrazinooxazepine derivatives
US8314088B2 (en) 2009-06-15 2012-11-20 Takeda Pharmaceutical Company Limited Pyrazinooxazepine derivatives
US8318722B2 (en) 2009-06-15 2012-11-27 Takeda Pharmaceutical Company Limited Pyrazinooxazepine derivatives
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
US10034859B2 (en) 2015-07-15 2018-07-31 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
US11304932B2 (en) 2015-07-15 2022-04-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Also Published As

Publication number Publication date
EA200300183A1 (ru) 2003-08-28
BR0112661A (pt) 2003-06-24
YU2603A (sh) 2006-05-25
EA006604B1 (ru) 2006-02-24
KR20030036599A (ko) 2003-05-09
KR100845450B1 (ko) 2008-07-10
HUP0301346A3 (en) 2005-05-30
HUP0301346A2 (hu) 2003-08-28
IL154057A0 (en) 2003-07-31
AU8273401A (en) 2002-02-05
ZA200210234B (en) 2004-03-18
EP1301476A1 (en) 2003-04-16
AU2001282734B2 (en) 2006-10-12
NZ523216A (en) 2005-05-27
PL360309A1 (en) 2004-09-06
CN1221254C (zh) 2005-10-05
NO20030304D0 (no) 2003-01-20
HK1057536A1 (en) 2004-04-08
SE0002754D0 (sv) 2000-07-21
JP2004504376A (ja) 2004-02-12
CA2411192A1 (en) 2002-01-31
MXPA03000548A (es) 2004-04-05
CN1443162A (zh) 2003-09-17
NO20030304L (no) 2003-03-12

Similar Documents

Publication Publication Date Title
AU2001282734B2 (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
AU2001282734A1 (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
Davies et al. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology
US6818639B2 (en) Pharmaceutical combination formulation and method of treatment with the combination
ES2757922T3 (es) Agonistas y composiciones del receptor 5-HT2C y métodos de uso
JP2011006431A (ja) アデノシンＡ２ａレセプターアンタゴニストの使用
JP2765845B2 (ja) 中止症候群の予防の治療薬
CA2332814C (en) Combination therapy for treatment of refractory depression
CN1335850A (zh) 化合物
WO2000072837A2 (en) Methods and compositions for the treatment of neuroleptic and related disorders using sertindole derivatives
HUP0303448A2 (hu) GABAA inverz agonisták nikotin receptor részleges agonistákkal, ösztrogénnel, szelektív ösztrogén modulátorokkal vagy E vitaminnal való kombinált alkalmazása észlelési rendellenességek kezelésére
AU2004204827A1 (en) Method of treating nausea, vomiting, retching or any combination thereof
CA2167004C (en) Agent for treating mental disorders associated with cerebrovascular disorders
WO2001095902A1 (en) A composition comprising a combination of receptor agonists and antagonists
TW200815009A (en) Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof
WO2001095902A9 (en) A composition comprising a combination of receptor agonists and antagonists
JP4740152B2 (ja) 末梢性５−ｈｔ受容体の修飾因子
WO2002036113A1 (en) Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
ES2360164A1 (es) Ligandos de 5ht6 en el aumento de peso inducido por fármacos.
SK9002001A3 (en) 5ht1 antagonists for antidepressant therapy
V Ivachtchenko et al. Small molecule 5-HT6R ligands: A comprehensive insight into their selectivity and activity
Steiner et al. D4/5-HT2A Receptor antagonists: LU-111995 and other potential new antipsychotics in development
JP2010506884A (ja) Ｎｋ−１受容体アンタゴニストおよびｓｓｒｉを含む、耳鳴、聴力障害または耳鳴と聴力障害の治療用組成物
EA000758B1 (ru) Способ лечения биполярного расстройства
HK1057536B (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-26/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001961472

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2411192

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 523216

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002/10234

Country of ref document: ZA

Ref document number: 200210234

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020037000321

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001282734

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/000548

Country of ref document: MX

Ref document number: 154057

Country of ref document: IL

Ref document number: 109/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 018131549

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 200300183

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2001961472

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037000321

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 523216

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 523216

Country of ref document: NZ